miércoles, 16 de septiembre de 2015

Investigació i desenvolupament - (Switzerland) Lab Specialist - Immunology & Inflam

(Switzerland) Lab Specialist - Immunology & Inflam

: Roche
: The new Immunology and Inflammation Discovery group, part of the Roche Pharma Research and Early Development (pRED) based in Basel, is a multidisciplinary team of scientists with the goal of translating biology-driven discoveries into innovative drugs for unmet medical need of immune and inflammatory conditions. The Discovery group has opening for Research Associate Scientist positions to support the ongoing target discovery efforts The successful candidates will have extensive discovery and development experience in the field of inflammation with an emphasis on developing, validating, and performing immunochemical, biochemical, enzymatic, and cell-based assays to support target identification. In addition, the individuals will be expected to incorporate assay automation in his/her daily work and employ novel assay technologies. In this position they will:
Characterize immune cell subsets in different animal models and humans (by means of flow cytometry-based approaches, immunohistochemistry, etc.)
Isolate immune cell subsets and perform immunological assays in vitro and ex vivo
Perform cell cultureRequisits
The ideal candidate will have a BS or MS in Immunology, Biochemistry, Cell Biology or a related field with at least 6 years of biotechnology or biopharmaceutical experience. He/She is expected to have excellent organizational skills, to be detail-oriented and fully commited to team work.
Extensive hands-on experience in assay development applying multiple assay technologies
Good experience in multi-parametric flow cytometry-based techniques and immunological assays
Strong communication, interpersonal, and organizational skills
A high degree of self-motivation, flexibility and ability to independently conduct experiments
Interest in working in a multidisciplinary and multinational environment
Good knowledge of English

: 0
: 0
: 0
via FA RSS Más Información Aquí...